TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
In the News
Our Interim Executive Director and Director of Research, Denise Robinson, recently represented epithelioid hemangioendothelioma (EHE) patients at the 2024 ASCO Annual Meeting in Chicago, Illinois, where nearly 40,000 global oncology professionals convened. The American Society of Clinical Oncology (ASCO), is the world’s leading organization for oncology, bringing together advocates, healthcare providers, and related professionals to […]
Read More
On May 28, 2024, Ikena Oncology announced they are discontinuing the development of IK-930. We share your frustration and disappointment and understand the devastating impact felt by patients. Following this announcement, we met with Ikena to impress upon them the urgency and importance that patients deriving benefits from IK-930 continue to have access to the […]
Read More
In March Denise Robinson, Director of Research for The EHE Foundation attended the ESMO Sarcoma and Rare Cancers Congres 2024 in Lugano, Switzerland. This congress brought together world-renowned experts including researchers and clinicians, to present and discuss the latest advancements in the treatment of sarcomas and rare cancers. Topics ranged from the role of immune […]
Read More
Under the umbrella of the Connective Tissue Oncology Society (CTOS), the Ultra-rare Sarcoma Working Group, a broad group representing the global sarcoma community, including clinicians, scientists, patient advocates, and non-profit organizations has come together to establish a consortium, PUSH, to collect and make the best use of all available evidence to facilitate the development of […]
Read More
On Saturday, February 24, 2024, Denise Robinson, Director of Research provided an update to the global EHE community focused on ‘Patient-Powered EHE Research’. Denise highlighted research projects The EHE Foundation is funding and supporting through resources, and projects initiated by the foundation including the EHE Global Patient Registry and EHE Biobank. Denise highlights progress made […]
Read More
Ikena Oncology has shared that on December 14th, 2023, the Food and Drug Administration (FDA) granted Orphan Drug Designation to IK-930 for the treatment of epithelioid hemangioendothelioma (EHE). We are excited about this designation following initial positive data from the IK-930 Phase I clinical trial published in Ikena’s November 9th press release. What does this […]
Read More